A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

Liu, Joyce F

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. [electronic resource] - European journal of cancer (Oxford, England : 1990) Sep 2013 - 2972-8 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural

1879-0852

10.1016/j.ejca.2013.05.020 doi


Administration, Oral
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Breast Neoplasms--drug therapy
Capsules
Carcinoma, Ovarian Epithelial
Diarrhea--chemically induced
Dose-Response Relationship, Drug
Drug Administration Schedule
Fatigue--chemically induced
Female
Humans
Middle Aged
Nausea--chemically induced
Neoplasm Recurrence, Local
Neoplasms, Glandular and Epithelial--drug therapy
Ovarian Neoplasms--drug therapy
Phthalazines--administration & dosage
Piperazines--administration & dosage
Poly(ADP-ribose) Polymerase Inhibitors
Quinazolines--administration & dosage
Receptor, ErbB-2--metabolism
Receptors, Estrogen--metabolism
Receptors, Progesterone--metabolism
Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors
Tablets
Treatment Outcome